Articles

Outcomes-Based Drug Contracts Do Not Move Us Closer to Value

What steps are needed to make outcomes-based contracting a value-based approach?
Originally published on 06/21/2017 in Morning Consult

Frequently Asked Questions

What is value-based pricing?

Value-based pricing is when the price of a drug is based on its measured benefits, for instance, in clinical trials leading to its approval. Methods used to determine value-based prices are transparent, reproducible and data driven.

What is outcomes-based contracting?

Outcomes-based contracting refers to arrangements between manufacturers and payers, in which the manufacturer is obligated to issue a refund or rebate to the payer that is linked to how well the therapy performs in a real-world population. This refund or rebate is off of a list price that the manufacturer sets. The methods manufacturers use to generate list prices are typically opaque, inconsistent, and driven more by market factors than clinical data. These methods are often referred to, by manufacturers as “pricing to what the market will bear”.

What is the difference between value-based pricing and outcomes-based contracting?

We can look to Amgen’s recent outcomes-based agreement with Harvard Pilgrim for its cholesterol medication, Repatha, to illustrate the difference.

Amgen has agreed to refund Harvard Pilgrim the cost of medication for patients who have a heart attack or stroke, an estimated 3.5% of individuals on the drug. This equates to a reduction in annual list price from $14,100 to $13,620. In contrast, the Institute for Clinical and Economic Review last reported that a value-based price for Repatha would be $2,200 to $5,000 per year, one third to one fifth the expected price resulting from the outcomes-based contract.

ICER’s value-based price estimate is now expected to fall even further, as the original calculations were based on a meta-analysis of predicted reductions in mortality using LDL cholesterol reported in various trials, which was the only measure available at the time. Results from the recently concluded FOURIER trial, however, showed no mortality benefit. Consequently, ICER announced a planned update to their original report to reflect the lower than expected benefit from Repatha, which will cause the value-based price to be an even smaller fraction of the outcomes-based price. Meanwhile, Amgen has raised the price of Repatha by 3% since launch.

Observed treatment effects in FOURIER trial vs. initial ICER estimates.

Source: Institute for Clinical and Economic Review. Evolocumab for Treatment of High Cholesterol: Clinical Effectiveness, New Evidence Update. September 11, 2017. https://icer.org/wp-content/uploads/2020/10/ICER_PCSK9_NEU_091117.pdf

 

What do pharmaceutical corporations say they need to engage in outcomes-based contracting?

The pharmaceutical industry has claimed that several statues and regulations need to be rolled back in order for outcomes-based contracting to be feasible. Their requests include exemptions from

  1. Medicaid Best Price
  2. Off-label promotion regulation
  3. Anti-kickback statute

Are these statutes and regulations really such a barrier?

Medicaid Best Price

Outcomes-based contracts have been announced in the United States for Repatha, Praluent, Entresto, Actonel, and Enbrel, among others. It seems unlikely that these contracts could be in the field and violating current Medicaid Best Price rules.

The math also does not support waiving the rule. The current Best Price standard for brand drugs is a 23% discount below AMP. Refunds to plans are probably not 100% money-back guarantees for specific patients, but instead averaged into the rebate across all patients. In order to dip below the 23% discount, failures would have to be so frequent that it should raise questions as to whether the average price is correct in the first place. For example, a refund for Repatha patients who have a heart attack or stroke would only amount to around 3.5% (according to FOURIER trial results), which would not cross the Medicaid Best Price threshold.

Finally, the claim that Best Price needs to be waived so outcomes-based contracts can be executed in Medicare is incorrect. The rule does not apply to Medicare Part D, so any discounts given to a Part D plan would not affect Medicaid Best Price.

Off-label promotion

The 21st Century Cures Act and recent FDA draft guidance have added significant flexibility to promotional activities by pharmaceutical corporations. Based on existing reports, many outcomes-based contracts already incorporate endpoints that are not included in the FDA-approved prescribing information.

Anti-kickback statute

It is hard to gauge the relative impact of the anti-kickback statue. Because the promise of outcomes-based contracts resulting in value-based prices is uncertain, it would be safer for OIG to provide protections for specific contracts, rather than take action on the statute as a whole.

How feasible are outcomes-based contracts in practice?

The experience so far casts doubt on the practical feasibility of such contracts. In fact, most of the barriers to their use are logistical; in a survey conducted with various healthcare stakeholders, only one of the three aforementioned barriers was listed (Medicaid Best Price). These other practical concerns, outlined by Garrison et al., will continue to limit the use of outcomes-based contracts, even if the requested policy concessions are granted.

What’s the potential for outcomes-based contracting?

Italy’s healthcare system has fully embraced outcomes-based contracts, which has only led to aggregate savings of 3.3% of their total drug spending from 2006-2012.

Key References:

For value-based pricing:

Bach, Peter B., and Steven D. Pearson. “Payer and policy maker steps to support value-based pricing for drugs.” JAMA 314.23 (2015): 2503-2504.

Neumann, Peter J., and Joshua T. Cohen. “Measuring the value of prescription drugs.” New England Journal of Medicine 373.27 (2015): 2595-2597.

For outcomes-based contracting:

Carlson, Josh J., et al. “Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.” Health policy 96.3 (2010): 179-190.

Garrison, Louis P., et al. “Performance-based risk-sharing arrangements’ good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.” Value in Health 16.5 (2013): 703-719.

Garrison Jr, Louis P., et al. “Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.” The American journal of managed care 21.9 (2015): 632-640.

Neumann, Peter J., et al. “Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.” Health Affairs30.12 (2011): 2329-2337.

Sachs, Rachel, Nicholas Bagley, and Darius N. Lakdawalla. “Innovative Contracting for Pharmaceuticals and Medicaid’s Best-Price Rule.” (2017).

Share

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep…
Pharmaceutical manufacturers push for adoption of outcomes-based contracting as a means of achieving a value-based price, but such contracts are ill-suited to do so.
Annals of Internal Medicine 06/19/2018
Outcomes-Based Drug Contracts Do Not Move Us Closer to Value
What steps are needed to make outcomes-based contracting a value-based approach?
Morning Consult 06/21/2017
The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.
Relentless Health Value 12/10/2020
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Drop in Cancer Deaths Reflect Failures of Our Society. Really.
Despite declining cancer death rates, the nation still presents societal failures to improve the state of our population's health.
The Boston Globe 02/21/2020
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now…
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
STAT News 10/11/2019
Time to Throw in the Towel on Biosimilars
Peter Bach and Mark Trusheim of MIT Sloan School of Management underscore the drawbacks of Washington's preferred solution to introduce competition for biologics, the biosimilar model.
The Wall Street Journal 08/21/2019
Mortgaging New Treatments Kicks the Can on High Drug Prices
The launch price for one-time gene therapy Zolgensma presents various implications.
Morning Consult 07/09/2019
A $475,000 price tag for a new cancer drug: crazy…
Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.
STAT News 08/31/2017
US Drug Prices And R&D, Take 2: A Reply To…
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog 07/27/2017
Newsletter

Stay up to date on our work and news